Hydroquinone

Mechanism of Action

Hydroquinone acts as a skin-depigmenting agent by inhibiting melanin synthesis. It inhibits the conversion of L-3,4-dihydroxyphenylalanine (L-DOPA) to melanin by inhibiting tyrosinase because of its structural similarity to melanin precursors.[7] However, repigmentation may occur following sun exposure.

The Pathway of Melanin Synthesis

1. Hydroxylation of L-phenylalanine to L-tyrosine.
2. Tyrosinase hydroxylates L-tyrosine to L-DOPA.
3. Tyrosinase further oxidizes L-DOPA to dopaquinone.
4. Production of eumelanin and pheomelanin results in black to brown and yellow to red color of skin.[10]

Pharmacokinetics

The onset and duration of depigmenting effects associated with hydroquinone vary among individuals. Human in vivo studies have demonstrated systemic absorption of approximately 35% to 45% following topical application of 2% hydroquinone formulations.[11][12]

Administration

Available Dosage Forms

Hydroquinone is available in 2% and 4% concentrations.[3] Hydroquinone is available in cream, emulsion, gel, and solution formulations. Multiple studies have shown that optimal results are achieved when hydroquinone is used in combination with a retinoid and a corticosteroid. The most widely used triple-combination cream contains hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%.[7] Combination therapy with other agents requires a prescription from a dermatologist.

Adult Dosage

Hydroquinone is used only topically as a depigmenting agent. A thin layer of hydroquinone should be applied with the fingertips and gently rubbed into the face or other affected areas once or twice daily for up to 3 months. If no improvement is observed after 2 to 3 months, hydroquinone should be discontinued. Even application over the entire face is essential to prevent uneven pigmentation, and concurrent use of sunscreen is required to protect against UV-induced pigmentation. Physicians recommend discontinuing treatment for several months before restarting therapy to reduce the risk of adverse effects. Hydroquinone may also be applied only on weekends or 3 times weekly for extended maintenance therapy with minimal complications.[7] Clinical outcomes vary among patients.

Specific Patient Populations

Hepatic impairment: No dosage adjustment is provided in the manufacturer's labeling.

Renal impairment: No dosage adjustment is provided in the manufacturer's labeling.

Pregnancy considerations: Adequate animal reproduction studies evaluating topical hydroquinone have not been performed. Additionally, the extent of systemic absorption following topical application remains unclear. Current studies have not demonstrated an increased risk of malformations or adverse effects in pregnant women; however, exposure should be minimized unless the benefits of therapy outweigh the associated risks.

Breastfeeding considerations: Data regarding the excretion of hydroquinone into human breast milk are unavailable. Therefore, caution is advised when hydroquinone is used in breastfeeding women.

Adverse Effects

The manufacturer's labeling does not list any adverse reactions.

Postmarketing reports of adverse events include:[7][3][13]

• Irritation
• Allergic contact dermatitis [14]
• Erythema
• Inflammation
• Xeroderma
• Stinging
• Ochronosis [15]

Exogenous ochronosis is the most clinically significant adverse effect of hydroquinone, presenting as blue-black or gray-brown discoloration with caviar-like papules. A 2022 systematic review identified 126 reported cases, predominantly among middle-aged women of African descent with Fitzpatrick skin types V–VI. Higher concentrations (>4%) and prolonged use beyond 3 months increase risk, with a median exposure duration of 5 years before clinical onset.[16] Mechanistic studies in 2025 clarified that ochronosis results from tyrosinase-driven hydroquinone metabolism, leading to dermal deposition of low-molecular-weight derivatives that bind to photodamaged collagen, rather than from inhibition of homogentisate dioxygenase.[17] Additionally, hydroquinone activates the TRPA1 receptor, which may explain the commonly reported adverse effects such as burning, erythema, and irritation.[18] Studies also suggest that hydroquinone can falsely elevate capillary glucose readings on a glucometer.[19]  Corneal changes, scleral thinning, and scleral abnormalities have been reported.[20] Clinical practice and human studies have not confirmed concerns regarding the carcinogenicity of hydroquinone cream.[7]

Contraindications

According to the manufacturer's labeling, there are no absolute contraindications to this medication. Caution is advised in patients with a history of allergic reactions or hypersensitivity to hydroquinone. Continuous or prolonged use may cause exogenous ochronosis in sun-exposed treated areas. Hydroquinone should be used cautiously with other medications that cause photosensitivity.

Monitoring

Careful monitoring for hypersensitivity reactions and long-term cutaneous irritation is essential during hydroquinone therapy, and treatment should be discontinued if these adverse effects occur. Rarely, patients may develop exogenous ochronosis, which requires immediate cessation of treatment and clinician assessment. Patient education regarding appropriate duration of use, sun protection, and early recognition of adverse effects is critical to minimizing preventable complications.

A 2022 systematic review and meta-analysis of investigator-blinded randomized controlled trials confirmed the efficacy of hydroquinone and triple-combination therapy for melasma, although the certainty of evidence varied across individual comparisons.[21] An international Delphi consensus published in 2025 by the Pigmentary Disorders Society reaffirmed supervised hydroquinone-based triple-combination creams as the current therapeutic gold standard, particularly for moderate to severe disease.[22]

Despite this established role, increasing attention has focused on alternative agents that may provide comparable efficacy with improved safety, tolerability, and suitability for long-term use. A 2025 randomized controlled trial demonstrated that both niosomal and conventional tranexamic acid 2%/niacinamide 2% formulations achieved efficacy comparable to hydroquinone 4% while producing fewer treatment-related adverse effects and lower posttreatment relapse rates.[23] Similarly, thiamidol (isobutylamido thiazolyl resorcinol) 0.2% showed noninferior clinical outcomes compared with hydroquinone 4% in randomized trials, supporting its role as a viable depigmenting agent.[24] Additional evidence indicates that hexylresorcinol 1% achieved efficacy comparable to hydroquinone 2% in a 12-week split-body trial without reported adverse events, suggesting a favorable safety profile.[25] Cysteamine 5% has also demonstrated measurable clinical benefit; however, its efficacy was inferior to hydroquinone 4%, with lower reductions in modified Melasma Area and Severity Index scores at 120 days (38% vs 53%), potentially limiting its role as monotherapy.[26] Topical retinoids remain important adjunctive or alternative therapies, with tazarotene 0.045% demonstrating favorable efficacy and tolerability over a 24-week treatment period.[27]

Collectively, current evidence supports short-term hydroquinone use (≤3 months) at concentrations of 4% or lower, with close clinical monitoring for adverse effects, whereas alternative agents may be preferable for maintenance therapy or for patients with sensitive skin or an increased risk of complications.[23][24][27][16] Across all therapeutic approaches, consistent use of broad-spectrum sunscreen covering both UV and visible light remains a critical component of melasma management, significantly enhancing treatment durability and overall clinical outcomes.[21][22]

Toxicity

Studies have not identified significant toxicity associated with the topical use of hydroquinone cream. Some studies have reported malignancies in animals exposed to large oral doses over extended periods.[3]

Hydroquinone in the Environment

Environmental hydroquinone may exert toxic effects in humans by promoting the generation of reactive oxygen species and oxidative stress, thereby increasing the potential for DNA damage. Hydroquinone is a major benzene metabolite and is known to be hepatotoxic and carcinogenic in industrial settings. Some studies suggest hydroquinone may promote tumor cell growth and suppress the immune response. Hydroquinone is used in photography and is present in dyes, paints, varnishes, oils, and motor fuels. In its oxidized form, hydroquinone is more toxic and less degradable. Hydroquinone demonstrates high toxicity to aquatic organisms and rodents and may induce leukemia, renal tubular cell tumors, and liver cancer. Studies have also shown that hydroquinone influences immune cell responses and may enhance allergic reactions by increasing interleukin-4 production and immunoglobulin E levels.[28]

Enhancing Healthcare Team Outcomes

The interprofessional healthcare team, including physicians, nurses, and pharmacists, plays an essential role in optimizing the safe and effective use of hydroquinone therapy. Patients should be counseled to use hydroquinone only as prescribed and for the shortest duration necessary, as prolonged or unsupervised use increases the risk of adverse effects, particularly exogenous ochronosis. Nursing staff can assist in reinforcing adherence to treatment instructions, including appropriate application technique, frequency of use, and the importance of concurrent photoprotection. Clinicians should educate patients about early signs of cutaneous irritation, hypersensitivity, allergic contact dermatitis, and paradoxical hyperpigmentation and should recommend prompt discontinuation of therapy if significant adverse reactions occur. Pharmacists are well positioned to review treatment duration, identify prolonged or inappropriate use of depigmenting therapies, counsel patients on sunscreen use, and communicate potential concerns to the prescribing clinician during refill encounters. Because exogenous ochronosis may present as progressive blue-black or gray-brown discoloration of treated skin, patients should be instructed to discontinue therapy and seek medical evaluation if these changes develop. A coordinated interprofessional team approach improves patient education, adherence, monitoring, and overall therapeutic outcomes.